The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of PU-H71, a novel HSP90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.
Srikanth R. Ambati
No relevant relationships to disclose
Eloisi Caldas Lopes
No relevant relationships to disclose
Kohji Kosugi
No relevant relationships to disclose
Ullas Mony
No relevant relationships to disclose
Ahmet Zehir
No relevant relationships to disclose
Andre L. Moreira
No relevant relationships to disclose
Paul A. Meyers
Honoraria - Millennium
Research Funding - Millennium
Gabriela Chiosis
No relevant relationships to disclose
Malcolm A.S. Moore
No relevant relationships to disclose